Join
Live feed
·
PRReleasevia Quantisnow
Legend Biotech Corporation logo

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
LEGN· Legend Biotech Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LEGN (Legend Biotech Corporation) and more on Quantisnow.